AkesoBio is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for cancer treatment. The company focuses on creating advanced monoclonal and bispecific antibodies, which are designed to target specific cancer cells and improve patient outcomes. AkesoBio primarily serves patients with various types of cancer, including relapsed or refractory classical lymphoma, squamous non-small cell lung cancer, and metastatic cervical cancer. Operating in the global biopharmaceutical market, AkesoBio's business model revolves around research and development, clinical trials, and regulatory approvals to bring their therapies to market. The company generates revenue through the sale of its approved drugs and potential licensing agreements with other pharmaceutical companies. Key milestones include the approval of Penpulimab by the National Medical Products Administration (NMPA) of China and the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). AkesoBio's commitment to innovation and patient care positions it as a leader in the oncology therapeutics space.

Keywords: biopharmaceutical, cancer treatment, monoclonal antibodies, bispecific antibodies, oncology, clinical trials, regulatory approvals, Penpulimab, NMPA, FDA.